News
Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback